Fusion Pharmaceuticals Inc.
FUSN · NASDAQ
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Market Cap | $1,780,233 | $702,436 | $179,530 | $309,515 |
| - Cash | $28,259 | $61,925 | $26,787 | $32,022 |
| + Debt | $64,547 | $50,331 | $52,628 | $50,622 |
| Enterprise Value | $1,816,521 | $690,842 | $205,371 | $328,115 |
| Revenue | $0 | $33,636 | $2,006 | $34 |
| % Growth | -100% | 1,576.8% | 5,800% | – |
| Gross Profit | -$361 | $33,275 | $962 | -$897 |
| % Margin | – | 98.9% | 48% | -2,638.2% |
| EBITDA | -$31,694 | -$25,186 | -$18,456 | -$23,801 |
| % Margin | – | -74.9% | -920% | -70,002.9% |
| Net Income | -$33,670 | -$28,179 | -$17,252 | -$25,175 |
| % Margin | – | -83.8% | -860% | -74,044.1% |
| EPS Diluted | -0.4 | -0.39 | -0.25 | -0.38 |
| % Growth | -2.6% | -56% | 34.2% | – |
| Operating Cash Flow | -$27,306 | -$16,935 | -$18,839 | -$19,584 |
| Capital Expenditures | -$1,334 | -$1,439 | -$473 | -$710 |
| Free Cash Flow | -$28,640 | -$18,374 | -$19,312 | -$20,294 |